Expanding Radiopharmaceutical Targeting Mechanisms with Novel Moieties to Harness Enhanced Specificity, Efficacy & Safety
Time: 11:00 am
day: Workshop B
Details:
The development of novel targeting moieties for radiopharmaceuticals has seen significant advancements, particularly in the context of targeting cancer cells and supporting tissues. These novel moieties include small peptides, cyclic peptides, bispecifics and nanobodies, each offering unique advantages in terms of specificity, stability, and pharmacokinetics.
Uncovering the latest understandings and developments across novel targeting approaches, this workshop will:
- Explore DEP Dendrimers as a platform for novel targeting moieties and payloads to achieve enhanced radioisotope specificity, efficacy and safety
- DEP dendrimers are being used to develop novel targeted radiopharmaceuticals that overcome delivery challenges to achieve optimal biodistribution, safety and efficacy of radioisotopes. Exploring in vivo demonstration of the ability of dendrimers to deliver targeted radiotherapies to achieve favorable imaging and therapeutic outcomes.
- Assessing novel approaches by comparing and contrasting approaches
